February 26, 2016


Baxalta, Precision BioSciences Partner in Up-to-$1.7B Immuno-Oncology Collaboration

Baxalta and Precision BioSciences will partner to develop allogeneic chimeric antigen receptor T cell (CAR-T) therapies, in a collaboration that could generate up to $1.7 billion for Precision. The companies said their collaboration will combine Baxalta’s immuno-oncology candidates and global-scale operations with Precision’s ARCUS genome editing platform technology. The CAR-T cell therapies will address what Baxalta and Precision called areas of major unmet need in multiple unspecified cancers.


To read the full article, click here.